Hansa Biopharma AB Cash Flow-to-Debt Ratio
Hansa Biopharma AB cash flow-to-debt ratio. Hansa Biopharma AB (HNSA) has a Cash Flow-to-Debt Ratio of -0.09x as of June 2025, meaning its operating cash flow of Skr-111.70 Million could theoretically repay 0% of its total liabilities (Skr1.28 Billion) in one year. See Hansa Biopharma AB leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Hansa Biopharma AB (2008–2024)
Cash flow-to-debt ratio of Hansa Biopharma AB from 2008 to 2024. Historical debt coverage capacity for Hansa Biopharma AB across 17 annual periods. Check Hansa Biopharma AB (HNSA) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Hansa Biopharma AB Cash Flow-to-Debt Ratio by Year (2008–2024)
Hansa Biopharma AB cash flow-to-debt ratio by year from 2008 to 2024. Year-by-year debt coverage analysis for Hansa Biopharma AB. For the full cash flow conversion analysis, see HNSA cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.49x | Skr-674.88 Million | Skr1.39 Billion | ▲ +23.8% |
| 2023 | -0.64x | Skr-755.65 Million | Skr1.19 Billion | ▼ -37.5% |
| 2022 | -0.46x | Skr-502.73 Million | Skr1.08 Billion | ▲ +75.4% |
| 2021 | -1.89x | Skr-481.17 Million | Skr255.24 Million | ▼ -24.9% |
| 2020 | -1.51x | Skr-290.27 Million | Skr192.37 Million | ▲ +54.3% |
| 2019 | -3.30x | Skr-334.77 Million | Skr101.42 Million | ▼ -37.1% |
| 2018 | -2.41x | Skr-204.56 Million | Skr84.94 Million | ▲ +20.2% |
| 2017 | -3.02x | Skr-150.10 Million | Skr49.75 Million | ▲ +13.9% |
| 2016 | -3.51x | Skr-94.56 Million | Skr26.98 Million | ▲ +23.8% |
| 2015 | -4.60x | Skr-57.80 Million | Skr12.56 Million | ▲ +12.2% |
| 2014 | -5.24x | Skr-23.62 Million | Skr4.51 Million | ▼ -79.7% |
| 2013 | -2.92x | Skr-14.87 Million | Skr5.10 Million | ▲ +63.9% |
| 2012 | -8.07x | Skr-20.63 Million | Skr2.56 Million | ▼ -84.1% |
| 2011 | -4.39x | Skr-27.14 Million | Skr6.19 Million | ▼ -36.6% |
| 2010 | -3.21x | Skr-18.09 Million | Skr5.64 Million | ▼ -207.9% |
| 2009 | -1.04x | Skr-13.79 Million | Skr13.23 Million | ▲ +72.3% |
| 2008 | -3.77x | Skr-15.58 Million | Skr4.13 Million | — |